UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (Exact name of re ...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2020 Earnings Conference Call October 30, 2020 8:30 AM ET Company Participants Patrick O'Brien - Investor Relations John Higgins - Chief Executive Officer Matt Korenberg - Executive Vice President, Finance & Chief Financial Officer Matt Foehr - President & Chief Operating Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Balaji Prasad - Barclays Joe Pantginis - H.C. Wainwright Scott Henry - Roth Capital Dana Flanders - Guggenhe ...

Q3 RESULTS AND FULL-YEAR 2020 OUTLOOK October 30, 2020 Nasdaq: LGND 2 SAFE HARBOR STATEMENT The following presentation contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this presentation. Words such as "plans," "believes," "expects," "could," and "will," and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, financial projections, expectations ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Per ...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2020 Earnings Conference Call August 3, 2020 8:30 AM ET Company Participants Patrick O'Brien - Investor Relations John Higgins - Chief Executive Officer Matt Korenberg - Executive Vice President, Finance & Chief Financial Officer Matt Foehr - President & Chief Operating Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Joe Pantginis - H.C. Wainwright Balaji Prasad - Barclays Larry Solow - CJS Securities Scott Henry - Roth Capit ...

Q2 Results and Full-Year 2020 Outlook ® August 3, 2020 NASDAQ: LGND 2 Safe Harbor Statement The following presentation contains forward-looking statements by Ligand that involve risks and uncertainties. Words such as "plans," "believes," "expects," "could," and "will," and similar expressions, are intended to identify forwardlooking statements. These forward-looking statements include, without limitation, financial projections, expectations regarding research and development programs and manufacturing capac ...

Corporate Presentation Delivering Innovation for Major Medical Needs ® 17th Annual Craig-Hallum Conference May 2020 NASDAQ: LGND 2 Safe Harbor Statement The following presentation contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this presentation. Words such as "plans," "believes," "expects," "projects," "could," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. These forw ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From ______ to ______ . Commission File Number: 001-33093 LIGAND PHARMACEUTICALS INCORPORATED Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section ...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2020 Results Earnings Conference Call May 6, 2020 4:30 PM ET Company Participants Patrick O'Brien - Investor Relations John Higgins - Chief Executive Officer Matt Korenberg - Executive Vice President, Finance and Chief Financial Officer Matt Foehr - President and Chief Operating Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Balaji Prasad - Barclays Peter Lukas - CJS Securities Dana Flanders - Guggenheim Securities, LLC Scot ...

Q1 Results and Full Year 2020 Outlook ® May 6, 2020 Nasdaq: LGND 2 Safe Harbor Statement The following presentation contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this presentation. Words such as "plans," "believes," "expects," "projects," "could," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, financial pr ...